Alzheimer's Assocation Research only
All of alz.org
  • Go to Alz.org
  • Research Center
  • AAIC
  • ISTAART
  • Journal
  • Grants
  • TrialMatch
  • Press
  • Donate
  • Contact Us
Home
Science and Progress
Clinical Trials
Funding and Collaboration
You can Help
Stay Current
Video and Resources

Text Size

Small text Medium text Large text

Research Grants 2017


To view an abstract, select an author from the vertical list on the left.

2017 Grants - Pahan

PPARalpha in APP Metabolism

Kalipada Pahan, Ph.D.
Rush University Medical Center
Chicago, Illinois

2017 Zenith Fellows Award Program

Can novel factors produced in the brain help prevent the formation of toxic beta-amyloid?

Background
One of the hallmarks of Alzheimer’s disease is the accumulation of beta-amyloid protein fragments into plaques inside the brain. Beta-amyloid protein fragments are formed from the processing of its parent protein called amyloid precursor protein (APP). However, APP can be metabolized by alternative processes that do not allow the formation of beta-amyloid. It is possible that stimulating this “non-amyloid” pathway could help prevent the build-up toxic beta-amyloid in the brain.

In previous studies, Kalipada Pahan, Ph.D., and colleagues have found that activation of a protein called peroxisome proliferator-activated receptor (PPAR) appears to control the processing of APP in nerve cells. More research is needed to better understand these mechanisms and identify new ways to regulate APP non-amyloidogenic processing as a potential way to slow or prevent beta-amyloid accumulation in the brain during Alzheimer’s disease.

Research Plan
Dr. Pahan and team have recently identified three novel compounds that are found in high levels in the healthy brain, specifically in a region called the hippocampus which is important for memory function. These novel compounds can activate PPAR which could help shift APP to be processed down the non-amyloid pathway. For their current studies, the researchers will administer these novel compounds to Alzheimer’s-like mice and determine if they can effectively lower levels of beta-amyloid in the brain.

Impact
Results from this study could improve our understanding of the fundamental mechanisms involved in the processing of APP and the formation of beta-amyloid. Importantly, these findings may identify novel compounds that prevent the build-up of beta-amyloid in the brain and could potentially be developed as treatments to slow, halt or prevent the progression of Alzheimer’s disease.


Alzheimer's Association International Conference | July 16-20, 2017, London, England

Abstract Submissions Now Open

The Scientific Program Committee is now accepting submissions for poster
presentations, oral presentations and featured research sessions.